Wedbush Has Positive Forecast for Biogen Q2 Earnings

Biogen Inc. (NASDAQ:BIIB) – Research analysts at Wedbush lifted their Q2 2025 earnings estimates for Biogen in a report issued on Wednesday, April 16th. Wedbush analyst L. Chico now expects that the biotechnology company will post earnings per share of $4.21 for the quarter, up from their prior forecast of $3.98. The consensus estimate for Biogen’s current full-year earnings is $15.83 per share. Wedbush also issued estimates for Biogen’s Q3 2025 earnings at $4.12 EPS, Q4 2025 earnings at $3.87 EPS, FY2025 earnings at $15.71 EPS, Q3 2026 earnings at $4.33 EPS, FY2028 earnings at $20.48 EPS and FY2029 earnings at $21.14 EPS.

Biogen (NASDAQ:BIIB) last posted its quarterly earnings data on Wednesday, February 12th. The biotechnology company reported $3.44 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.43 by $0.01. Biogen had a net margin of 16.87% and a return on equity of 14.98%.

A number of other research firms also recently issued reports on BIIB. Citigroup decreased their target price on Biogen from $160.00 to $145.00 and set a “neutral” rating for the company in a research report on Thursday, February 13th. Piper Sandler reiterated a “neutral” rating and issued a $135.00 price objective (down from $138.00) on shares of Biogen in a report on Tuesday, February 18th. HC Wainwright decreased their price objective on shares of Biogen from $300.00 to $241.00 and set a “buy” rating for the company in a research note on Thursday, February 13th. The Goldman Sachs Group cut their target price on shares of Biogen from $281.00 to $245.00 and set a “buy” rating for the company in a research note on Thursday, February 13th. Finally, Truist Financial reduced their price objective on shares of Biogen from $220.00 to $210.00 and set a “buy” rating for the company in a research report on Thursday, February 13th. Eighteen equities research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $213.15.

Biogen Price Performance

BIIB opened at $118.61 on Friday. Biogen has a fifty-two week low of $110.04 and a fifty-two week high of $238.00. The firm has a 50-day moving average of $134.71 and a 200 day moving average of $152.19. The firm has a market cap of $17.36 billion, a P/E ratio of 10.60, a PEG ratio of 1.51 and a beta of 0.06. The company has a debt-to-equity ratio of 0.27, a quick ratio of 0.90 and a current ratio of 1.35.

Insiders Place Their Bets

In related news, Director Stephen A. Sherwin sold 8,760 shares of Biogen stock in a transaction that occurred on Friday, March 7th. The stock was sold at an average price of $150.02, for a total value of $1,314,175.20. Following the sale, the director now owns 11,318 shares of the company’s stock, valued at approximately $1,697,926.36. This trade represents a 43.63 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 0.16% of the company’s stock.

Institutional Investors Weigh In On Biogen

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Inspire Trust Co. N.A. lifted its stake in Biogen by 58.5% in the third quarter. Inspire Trust Co. N.A. now owns 10,900 shares of the biotechnology company’s stock worth $2,113,000 after acquiring an additional 4,025 shares during the period. Assenagon Asset Management S.A. grew its holdings in shares of Biogen by 0.3% during the 4th quarter. Assenagon Asset Management S.A. now owns 43,460 shares of the biotechnology company’s stock worth $6,646,000 after acquiring an additional 111 shares during the period. Amundi boosted its position in shares of Biogen by 35.6% during the fourth quarter. Amundi now owns 1,216,990 shares of the biotechnology company’s stock valued at $183,461,000 after purchasing an additional 319,478 shares in the last quarter. Centre Asset Management LLC lifted its position in Biogen by 7.7% during the fourth quarter. Centre Asset Management LLC now owns 51,530 shares of the biotechnology company’s stock valued at $7,880,000 after buying an additional 3,698 shares during the period. Finally, Integrated Quantitative Investments LLC purchased a new stake in shares of Biogen in the 4th quarter worth about $407,000. 87.93% of the stock is currently owned by institutional investors.

About Biogen

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer’s disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.